Two board appointments at EyeGate Pharma
This article was originally published in Scrip
EyeGate Pharma (US) has appointed Paul Chaney chairman of the board and Dr Morton Goldberg as director. Mr Chaney is a consultant at Eyetech, which recently spun out of (OSI) Eyetech, OSI's eye care subsidiary. He was previously executive vice-president of OSI Pharmaceuticals and president of (OSI) Eyetech. Dr Goldberg is a Joseph E Green professor of ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.